2022-08-08T16:44:07-05:00 2021-09-30 ERNST & YOUNG US LLP 18101 VON KARMAN AVE STE 1700 IRVINE CA 92612 990 2020-10-01 753065445 THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE % TRACY KARNS TRAN 6023438400 445 N 5TH STREET Suite 600 PHOENIX AZ 85004 MANUEL ESTRADA CFO 6023438400 2022-08-02 true Manuel Estrada 999009999 KARA ADAMS P00023315 9497942300 2022-08-04 3 2020 2022-09-23 18:48:47Z JEFFREY M TRENT PHD 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 242376354 false X WWW.TGEN.ORG X 2002 AZ SEE SCHEDULE O X 12 9 469 48 0 54124639 36277806 23939255 25808862 406035 68189525 -4320536 45411597 74149393 175687790 0 0 0 0 37899661 40026832 0 0 0 40903399 59165763 78803060 99192595 -4653667 76495195 140363431 224233974 62473382 69704038 77890049 154529936 X SEE SCHEDULE O true false 23137146 0 0 TARGETED DIGITAL SEQUENCING BLOOD BIOPSY TECHNOLOGY (TARDIS) - SEE SCHEDULE O 12469676 0 9847910 CLINICAL GENOMICS REFERENCE LABORATORY - SEE SCHEDULE O 8515903 0 3947498 INTEGRATED CANCER - SEE SCHEDULE O 31856834 0 12013454 75979559 true true false true false false false false true true true false false false true true false true false false true false false false false false false false false true false false false true false false false true false false false true true true true true false false true 81 0 true 469 true false false false false false false false false false false true false X 12 9 false false false false true true true true true false false true true true true true true true true false X TRACY KARNS 6023438415 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 Robert Stone BD & VICE CHRM/COH CEO & PRES. 1.0 59.0 X X 0 3147496 558067 Jennifer Parkhurst Treasurer/COH CFO 1.0 59.0 X 0 1374742 313357 Jeffrey M Trent PhD BOARD MEMBER/PRES/SCIENCE DIR. 39.0 1.0 X X 0 1047178 249398 Gregory Schetina Secretary/COH General COUNSEL 1.0 59.0 X 0 1043947 215265 Teresa Burleson Chief Operating Officer 39.0 1.0 X 873615 0 23532 Daniel Von Hoff Physician in Chief 40.0 0.0 X 754185 0 71832 Cornelis Van Den Berg Former Officer 0.0 60.0 X 0 631148 74749 Sunil Sharma DEPUTY DIR OF CLINIC. SCIENCES 40.0 0.0 X 580764 0 22636 Julia Bridge Professor 40.0 0.0 X 419925 0 19087 Michael Berens Deputy Director of Research 40.0 0.0 X 403057 0 25120 Nicholas Schork Professor 40.0 0.0 X 404122 0 17054 Stephanie McRae GENERAL COUNSEL/ASST SECRETARY 40.0 0.0 X 395435 0 14428 Thomas Royce EXEC. DIR OF EMERG OPP (PT YR) 40.0 0.0 X 378862 0 20137 Timothy McDaniel Sr. VP of EmerG. Opp (PT YR) 40.0 0.0 X 365774 0 20835 Manuel Estrada CFO/Assistant Treasurer 39.0 1.0 X 352079 0 21354 Janine LoBello Ashion Clinical Lab Director 40.0 0.0 X 321818 0 18088 Kendall Jensen DEPUTY DIR. OF RESEARCH RES. 40.0 0.0 X 307500 0 20586 James Lowey Chief Information Officer 40.0 0.0 X 275730 0 21559 Galen Perry Sr. VP of MKTG & Communication 40.0 0.0 X 263628 0 24154 William J Post Board Member/Chairman 1.0 1.0 X X 0 0 0 Bennett Dorrance Board Member 1.0 1.0 X 0 0 0 David J Gullen MD Board Member 1.0 0.0 X 0 0 0 Sharon Harper Board Member 1.0 0.0 X 0 0 0 PAMELA KEHALY Board Member 1.0 0.0 X 0 0 0 CINDY PARSEGHIAN Board Member 1.0 0.0 X 0 0 0 TERRY PEETS Board Member 1.0 0.0 X 0 0 0 MARILYN QUAYLE Board Member 1.0 0.0 X 0 0 0 ANTHONY SCOTT Board Member 1.0 0.0 X 0 0 0 Richard Silverman Board Member 1.0 0.0 X 0 0 0 6096494 7244511 1751238 70 true true false GIRIKON LLC 15433 N TATUM BLVD SUITE 105 PHOENIX AZ 85032 CONSULTING SERVICES 332807 IMAGING ENDPOINTS II LLC 9700 N 91ST ST SUITE B-200 SCOTTSDALE AZ 85258 CONSULTING SERVICES 304327 ERNST YOUNG LLP PO BOX 846793 LOS ANGELES CA 90084 PROF. SERVICES 271615 BOOTH UDALL FULLER PLC 1255 W RIO SALADO PKWY SUITE 215 TEMPE AZ 85281 LEGAL SERVICES 250482 FIRSTSTRATEGIC 300 W CLARENDON AVE SUITE 460 PHOENIX AZ 85013 CONSULTING SERVICES 198000 5 18488385 11044321 6745100 36277806 RESEARCH CONTRACTS 541711 25808862 25808862 0 0 25808862 92533 92533 0 50072669 50072669 2708270 7369342 -4661072 0 -4661072 -4661072 1547987 125868227 1271720 58047502 276267 67820725 68096992 68096992 0 0 0 0 0 0 0 0 0 0 175687790 25808862 0 113601122 X 0 0 0 0 0 0 0 0 4023188 1563401 2459787 0 0 0 0 0 30020435 19583609 10436826 0 986277 614197 372080 0 2718130 1700547 1017583 0 2278802 1408480 870322 0 0 0 0 0 859830 408285 451545 0 615896 8213 607683 0 129600 129600 0 0 0 0 0 0 0 13083701 11487284 1596417 0 580043 433564 146479 0 15851745 15782698 69047 0 2900559 1849898 1050661 0 16270899 16270899 0 486255 164772 321483 0 99011 37381 61630 0 0 0 0 0 211185 52847 158338 0 114000 181976 -67976 0 0 0 0 0 7075085 4245051 2830034 0 454554 80766 373788 0 DUES & SUBSCRIPTIONS 171104 32133 138971 0 RECRUITMENT 169644 36491 133153 0 RELOCATION 72186 5195 66991 0 ALL OTHER EXPENSES 20466 31872 -11406 0 99192595 75979559 23213036 0 0 21756000 129097377 6429969 12190648 12511721 9007792 2479127 283706 131482 75000 0 0 0 0 1221231 0 1020134 2188666 73852648 22032352 62704442 51820296 0 0 0 0 0 0 9093349 8761703 23015976 10808786 140363431 224233974 11933405 18831065 0 0 3103374 2132540 0 0 213099 0 50000 50000 45982796 47372761 50000 50000 1140708 1267672 62473382 69704038 X 68899823 146224427 8990226 8305509 77890049 154529936 140363431 224233974 76495195 144692 0 0 0 X false true X true true true X 17588654 31879587 62343578 54124639 36879938 202816396 0 0 17588654 31879587 62343578 54124639 36879938 202816396 7040099 195776297 109024 4179409 3155820 3056541 52873472 63374266 0 5677144 5677144 271867806 105121318 0.72012 0.90470 X SCHEDULE A, PART II THE AMOUNTS INCLUDED IN SCHEDULE A, PART II CORRESPOND TO THE FOLLOWING PERIODS: COLUMN (E) 2020 : 10/01/2020-09/30/2021 COLUMN (D) 2019 : 10/01/2019-09/30/2020 COLUMN (C) 2018 : 10/01/2018-09/30/2019 COLUMN (B) 2017 : 10/01/2017-09/30/2018 COLUMN (A) 2016 : 01/01/2017-09/30/2017 (SHORT PERIOD) RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED false false false false false false false false true 129600 129600 false SCHEDULE C, PART II-B, LINE 1I THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) USES A THIRD PARTY COMMUNICATIONS AND PUBLIC AFFAIRS FIRM TO COORDINATE LOBBYING EFFORTS ON BEHALF OF TGEN THROUGH COMMUNICATIONS TO LOCAL GOVERNMENT, LEGISLATIVE AND FEDERAL OFFICIALS AND COMMUNITY LEADERS ON TGEN ACTIVITIES. false false 6696827 173542 517109 553954 6833524 6186285 378481 419824 287763 6696827 5088052 1373720 227248 502735 6186285 5355690 75833 182488 525959 5088052 5258044 46076 525676 4658 469448 5355690 0.00910 0.99090 false true true 0 47793362 6236392 41556970 3322739 1815644 1507095 19681497 12206915 7474582 3055050 1773401 1281649 51820296 0 DUE TO EMPLOYEE 457 (B) PLAN 1267672 1267672 X SCHEDULE D, PART V, LINE 4 TGEN FOUNDATION CLASSIFIES AS PERMANENTLY RESTRICTED NET ASSETS (1) THE ORIGINAL VALUE OF THE GIFT DONATED TO THE PERMANENT ENDOWMENT, (2) THE ORIGINAL VALUE OF SUBSEQUENT GIFTS DONATED TO THE PERMANENT ENDOWMENT, AND (3) ACCUMULATIONS TO THE PERMANENT ENDOWMENT MADE IN ACCORDANCE WITH THE DIRECTION OF THE APPLICABLE DONOR GIFT INSTRUMENT. TGEN FOUNDATION HAS A TEMPORARILY RESTRICTED ASSET WHICH HAS BEEN DESIGNED TO SUPPORT A SUMMER INTERN EACH YEAR AT TGEN. TGEN FOUNDATION'S POLICY FOR APPROPRIATING THE DISTRIBUTION OF ITS SUMMER INTERNSHIP PROGRAM ENDOWMENT HAS BEEN DESIGNED TO SUPPORT A GRANT TO TGEN FOR AN INTERN EACH YEAR FOR 25 YEARS. THE FOUNDATION CONSIDERED THE LONG-TERM EXPECTED RETURN ON ITS ENDOWMENT. TGEN FOUNDATION HAS A RESTRICTED ASSET FOR THE ESTABLISHMENT OF AN ENDOWED CHAIR IN BRAIN CANCER RESEARCH. TGEN FOUNDATION ALSO HAS A RESTRICTED ASSET WHICH ALLOWS THEM TO USE ANY INVESTMENT INCOME FOR OPERATING EXPENSES. SCHEDULE D, PART X, LINE 2 THE FOLLOWING PARAGRAPH IS FROM THE CITY OF HOPE CONSOLIDATED AUDITED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2021 (WHICH INCLUDES CITY OF HOPE, CITY OF HOPE NATIONAL MEDICAL CENTER, CITY OF HOPE MEDICAL FOUNDATION, BECKMAN RESEARCH INSTITUTE OF THE CITY OF HOPE, THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE AND ITS AFFILIATES, SOUTHERN CALIFORNIA RADIATION ONCOLOGY, LLC, ACCESSHOPE, LLC, AND CITY OF HOPE AUXILIARIES (AUXILIARIES)): FINANCIAL ACCOUNTING STANDARDS BOARD (FASB) ACCOUNTING STANDARDS CODIFICATION TOPIC ASC 740, INCOME TAXES, CLARIFIES THE ACCOUNTING FOR INCOME TAXES BY PRESCRIBING A MINIMUM RECOGNITION THRESHOLD THAT A TAX POSITION IS REQUIRED TO MEET BEFORE BEING RECOGNIZED IN THE FINANCIAL STATEMENTS. ASC 740 ALSO PROVIDES GUIDANCE ON DE-RECOGNITION, MEASUREMENT, CLASSIFICATION, INTEREST AND PENALTIES, DISCLOSURE, AND TRANSITION. THE GUIDANCE CONTAINED IN ASC 740 IS APPLICABLE TO PASS-THROUGH ENTITIES AND TAX-EXEMPT ORGANIZATIONS. CITY OF HOPE HAS NO SIGNIFICANT UNCERTAIN TAX POSITIONS OR TAX LIABILITY FOR TAX BENEFITS, INTEREST, OR PENALTIES ACCRUED AT SEPTEMBER 30, 2021 AND 2020. Europe (Including Iceland and Greenland) Program Services Research Services 128499 Middle East and North Africa Program Services Research Services 76461 North America Program Services Research Services 67917 South Asia Program Services Research Services 66450 East Asia and the Pacific Program Services Research Services 10208 349535 349535 false false false false false false SCHEDULE F, PART I, LINE 3, COLUMN (F) THE AMOUNTS REPORTED IN COLUMN (F) ARE DETERMINED BASED ON THE ACCRUAL METHOD OF ACCOUNTING. false true false false false false false true false Robert Stone BD & VICE CHRM/COH CEO & PRES. 0 1627789 0 1371000 0 148707 0 518344 0 39723 0 3705563 0 423000 Jeffrey M Trent PhD BOARD MEMBER/PRES/SCIENCE DIR. 0 847770 0 140000 0 59408 0 220536 0 28862 0 1296576 0 0 Manuel Estrada CFO/Assistant Treasurer 302826 0 47411 0 1842 0 8571 0 12783 0 373433 0 0 0 Jennifer Parkhurst Treasurer/COH CFO 0 848561 0 526181 0 0 0 265222 0 48135 0 1688099 0 74160 Gregory Schetina Secretary/COH General COUNSEL 0 605225 0 406179 0 32543 0 163370 0 51895 0 1259212 0 120612 Stephanie McRae GENERAL COUNSEL/ASST SECRETARY 299993 0 93600 0 1842 0 2837 0 11591 0 409863 0 0 0 James Lowey Chief Information Officer 244896 0 29000 0 1834 0 11339 0 10220 0 297289 0 0 0 Daniel Von Hoff Physician in Chief 749259 0 0 0 4926 0 60033 0 11799 0 826017 0 0 0 Michael Berens Deputy Director of Research 358766 0 20000 0 24291 0 13071 0 12049 0 428177 0 0 0 Sunil Sharma DEPUTY DIR OF CLINIC. SCIENCES 528342 0 30000 0 22422 0 8644 0 13992 0 603400 0 0 0 Timothy McDaniel Sr. VP of EmerG. Opp (PT YR) 278032 0 86500 0 1242 0 9679 0 11156 0 386609 0 0 0 Kendall Jensen DEPUTY DIR. OF RESEARCH RES. 291233 0 15000 0 1267 0 6154 0 14432 0 328086 0 0 0 Nicholas Schork Professor 376800 0 25000 0 2322 0 11332 0 5722 0 421176 0 0 0 Julia Bridge Professor 416361 0 0 0 3564 0 11307 0 7780 0 439012 0 0 0 Thomas Royce EXEC. DIR OF EMERG OPP (PT YR) 303322 0 75000 0 540 0 11381 0 8756 0 398999 0 0 0 Janine LoBello Ashion Clinical Lab Director 296884 0 24394 0 540 0 11380 0 6708 0 339906 0 0 0 Galen Perry Sr. VP of MKTG & Communication 225238 0 35600 0 2790 0 10900 0 13254 0 287782 0 0 0 Teresa Burleson Chief Operating Officer 505283 0 366490 0 1842 0 11387 0 12145 0 897147 0 0 0 Cornelis Van Den Berg Former Officer 0 485720 0 109409 0 36019 0 47626 0 27123 0 705897 0 0 SCHEDULE J, PART I, LINE 3 The President of TGEN is compensated by its related organization, City of Hope, which also determines the methods for establishing compensation. SCHEDULE J, PART I, LINE 4B THE CITY OF HOPE HAS A NON-QUALIFIED SECTION 457(F) EXECUTIVE SUPPLEMENTAL ACCUMULATION PLAN THAT IS DESIGNED AND MAINTAINED TO PROVIDE A SELECT GROUP OF MANAGEMENT OR HIGHLY COMPENSATED EMPLOYEES WITH DEFERRED COMPENSATION. THE PLAN VESTS AFTER THREE (3) FISCAL YEARS OF SERVICE AND THE VESTED TOTALS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN B (III). PRIOR TO VESTING, THE ANNUAL AMOUNTS ARE INCLUDED IN SCHEDULE J, PART II, COLUMN C. PURSUANT TO THE PLAN DOCUMENT, VESTED PARTICIPANTS ARE ENTITLED TO WITHDRAW FROM THEIR VESTED ACCOUNT AN AMOUNT EQUAL TO THE FEDERAL, STATE, LOCAL AND FICA TAXES THEY OWE. THESE AMOUNTS ARE REMITTED TO THE APPROPRIATE TAXING AUTHORITIES ON BEHALF OF THE PARTICIPANTS. DURING CALENDAR YEAR 2020 THE FOLLOWING INDIVIDUALS WITHDREW THE REFERENCED AMOUNTS TO COVER SUCH TAXES: ROBERT W. STONE $38,845 CORNELIS VAN DEN BERG $18,648 GREGORY SCHETINA $ 9,748 THESE AMOUNTS HAVE BEEN INCLUDED IN THE PARTICIPANTS INCOME ON SCHEDULE J, PART II, COLUMN B(III). SCHEDULE J, PART I, LINE 7 SOME OF TGEN'S OFFICERS AND KEY EMPLOYEES LISTED IN PART VII WERE PAID BONUSES WHICH WERE BASED ON ACCOMPLISHMENTS OF SPECIFIC MILESTONES AND/OR PERFORMANCE METRICS, AS APPROVED BY THE TGEN BOARD OF DIRECTORS. SCHEDULE J, PART II SOME OF TGENS OFFICERS AND KEY EMPLOYEES LISTED IN PART VII HAVE RETENTION AGREEMENTS THROUGH 2020 AND 2021. AMOUNTS ACCRUED BY TGEN DURING CALENDAR YEAR 2020 UNDER THESE AGREEMENTS HAVE BEEN REPORTED IN SCHEDULE J, PART II, COLUMN (C) AS DEFERRED COMPENSATION. BENNETT DORRANCE BOARD MEMBER See Part V X 50000 50000 false true true KENDALL JENSEN EMPLOYEE See Part V X 250000 75000 false true true 125000 SCHEDULE L, PART II, LINE 1, COLUMN (C) CAPITALIZE NEW ENTITY FORMED FOR BIOMARKER RESEARCH. SCHEDULE L, PART II, LINE 2, COLUMN (C) RELOCATION ASSISTANCE SALE OF EQUITY IN ASHION ANALYTICS LLC 2021-04-14 87310000 VALUATION 020478229 EXACT SCIENCES CORPORATION 555 ENDEAVOR LANE MADISON WI 53719 CORP false false false false SCHEDULE N, PART II In February 2021, TGen entered into an agreement with Exact Sciences to sell Ashion Analytics, through its wholly owned subsidiary PMED, for the purpose of accelerating worldwide patient care and precision medicine through sales channels and distribution networks. Regulatory approval was received and the sale was finalized in April 2021. FORM 990, PART I, LINE 1 and PART III, LINE 1 THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) IS A NONPROFIT BIOMEDICAL RESEARCH INSTITUTE FOCUSED ON DEVELOPING EARLIER AND SMARTER TREATMENTS BY EMPLOYING INNOVATIVE ADVANCES ARISING FROM THE HUMAN GENOME PROJECT AND APPLYING THEM TO THE DEVELOPMENT OF DIAGNOSTICS, PROGNOSTICS AND THERAPIES FOR CANCER, NEUROLOGICAL DISORDERS, DIABETES AND OTHER COMPLEX DISEASES. FORM 990, PART III, LINE 2 On January 11, 2021, TGen and Exact Sciences entered into a worldwide exclusive license to TGen's rights in its proprietary Targeted Digital Sequencing (TARDIS) blood biopsy technology. TARDIS was developed to be highly sensitive and customizable for each patient to detect trace amounts of tumor DNA in a patient's blood after his or her initial treatment. FORM 990, PART III, LINE 4A IN JANUARY 2021, TGEN AND EXACT SCIENCES ENTERED INTO A WORLDWIDE EXCLUSIVE LICENSE TO TGEN'S RIGHTS IN ITS PROPRIETARY TARGETED DIGITAL SEQUENCING (TARDIS) BLOOD BIOPSY TECHNOLOGY. THIS COMPELLING AND TECHNICALLY DISTINCT APPROACH WILL HELP EXPAND EXACT SCIENCES LEADERSHIP IN PRECISION ONCOLOGY AND OFFERS A DIFFERENTIATED PATIENT-SPECIFIC SOLUTION IN MINIMAL RESIDUAL DISEASE (MRD) TESTING. TARDIS WAS DEVELOPED TO BE HIGHLY SENSITIVE AND CUSTOMIZABLE FOR EACH PATIENT TO DETECT TRACE AMOUNTS OF TUMOR DNA IN A PATIENT'S BLOOD AFTER HIS OR HER INITIAL TREATMENT. ANALYSIS OF DNA SHED INTO A PATIENT'S BLOOD STREAM CAN PROVIDE A NONINVASIVE MEANS OF DETECTING THE PRESENCE OF A TUMOR. PATIENTS WHO HAVE UNDERGONE INITIAL TREATMENT MAY ONLY HAVE SMALL AMOUNTS OF TUMOR DNA IN THEIR BLOOD, WHICH CAN BE DIFFICULT TO DETECT WITH CONVENTIONAL TECHNOLOGY. IN A STUDY PUBLISHED IN SCIENCE TRANSLATIONAL MEDICINE, TARDIS DEMONSTRATED HIGH ACCURACY IN ASSESSING MOLECULAR RESPONSE AND RESIDUAL DISEASE DURING NEOADJUVANT THERAPY TO TREAT BREAST CANCER. TARDIS ACHIEVED UP TO 100-FOLD IMPROVEMENT BEYOND THE CURRENT LIMIT OF CIRCULATING TUMOR DNA DETECTION. TGen and Exact Sciences have entered into 5-year research collaboration. FORM 990, PART III, LINE 4B TGEN'S CLINICAL GENOMIC SEQUENCING IS PROVIDED THROUGH ASHION, A TGEN SPECIALTY LAB, ESTABLISHED IN 2011, WHICH IS A CAP ACCREDITED AND CLIA-CERTIFIED TESTING LABORATORY COMMITTED TO ACCELERATING THE ADOPTION OF PRECISION MEDICINE IN THE CARE STREAM. THE LABORATORY USES NEXT-GENERATION SEQUENCING TECHNOLOGY AND PROPRIETARY INFORMATICS SYSTEMS FOR ANALYSIS AND DRUG MATCHING. TUMOR/NORMAL SEQUENCING IS PERFORMED FOR ALL OF TGEN'S PRECISION MEDICINE ONCOLOGY TRIALS. THE LABORATORY ALSO PROVIDES GENOMIC SEQUENCING SERVICES FOR TGEN'S CENTER FOR RARE CHILDHOOD DISORDERS. THE TEST MENU INCLUDES CLIA-CERTIFIED EXOME AND RNA SEQUENCING. IN APRIL 2021, EXACT SCIENCES ACQUIRED ASHION FROM TGEN. THE ACQUISITION HELPED ACCELERATE THE DEVELOPMENT OF EXACT SCIENCES PRECISION ONCOLOGY PORTFOLIO, INCLUDING MRD AND OTHER SEQUENCING-BASED TESTS. TGen and Exact Sciences have entered into 10-year research collaboration. FORM 990, PART III, LINE 4C THE DIVISION OF INTEGRATED CANCER GENOMICS (ICG) IS UTILIZING STATE-OF-THE-ART MOLECULAR TECHNOLOGIES TO UNCOVER THE MULTIPLE DIMENSIONS OF MOLECULAR CHANGES THAT OCCUR IN CANCER, AND INTEGRATE THESE DATASETS TO CAPTURE A HIGH-RESOLUTION IMAGE OF THE TUMOR MOLECULAR LANDSCAPE. AMONG ICG FACULTY, THE DIVISION BOASTS AN AMAZING ARRAY OF COMPETENCIES INCLUDING GENOMIC PROFILING USING VARIOUS TECHNOLOGIES THAT INCLUDE NEXT-GENERATION SEQUENCING INCLUDING SINGLE-CELL, EPIGENETICS, NEOANTIGEN ANALYSIS, CANCER CELL BIOLOGY AND BIOINFORMATICS. ACROSS THE VARIOUS LABORATORIES, WE STUDY A MULTITUDE OF ADULT AND PEDIATRIC CANCERS, TRYING TO UNDERSTAND THE EVENTS THAT DRIVE CANCER PROGRESSION FROM PRIMARY TO ADVANCED METASTATIC DISEASE IN ADDITION TO UNDERSTANDING WHY AND HOW CANCER AFFECTS INDIVIDUALS FROM DIFFERENT ETHNICITIES AND ANCESTRAL BACKGROUNDS. ICG FACULTY ALSO ARE INVOLVED IN APPLYING HIGH-RESOLUTION GENOMIC TECHNOLOGIES TO PATIENT SAMPLES IN REAL TIME, DURING CLINICAL MANAGEMENT, TO ASSIST ONCOLOGISTS IN MAKING THERAPEUTIC RECOMMENDATIONS FOR CANCER PATIENTS. ICG IS DIRECTLY AIMING ITS EFFORTS TO DRIVE EARLIER DIAGNOSTICS AND SMARTER TREATMENTS TOWARDS PATIENTS. FORM 990, PART III, LINE 4D RESEARCH PROGRESSED MARKEDLY IN 2021, THIS INCLUDED A NUMBER OF RESEARCH AND CLILNICAL ADVANCES; PEER-REVIEWED SCIENTIFIC PAPERS; GRANTS AND CONTRACTS; EDUCATION AND OUTREACH EFFORTS; AND, NEAR- AND LONG-TERM OPPORTUNITIES TO ADVANCE AND STRENGTHEN TGEN'S PRESENCE IN BIOMEDICAL RESEARCH AND CLINICAL CARE. TGEN ACHIEVED SUCCESS ACROSS MULTIPLE AREAS. OUR VIRUS GENOMIC SEQUENCING ABILITIES INCREASED BY ALMOST 10-FOLD OVER THE PREVIOUS TWO YEARS (FUELED BY THE DELTA VARIANT). THIS WORK ENABLED THE DEVELOPMENT OF A 21ST CENTURY PUBLIC-HEALTH AND INFECTIOUS-DISEASE MONITORING SYSTEM, ENABLED BY BETTER, FASTER, MORE ACCURATE - AND COST EFFECTIVE - SEQUENCING TOOLS. TGEN, FOR EXAMPLE, WAS THE FIRST TO CONFIRM THE PRESENCE IN ARIZONA OF THE DELTA VARIANT, AND WE PREDICTED AS EARLY AS MAY THAT THIS EXTREMELY CONTAGIOUS FORM OF THE VIRUS WOULD DOMINATE NEW CASES IN ARIZONA. BY AUGUST, DELTA REPRESENTED 99 PERCENT OF THE STATE'S NEW CASES. THESE CAPABILITIES RESULTED IN MULTI-MILLION-DOLLAR CONTRACTS WITH THE ARIZONA DEPARTMENT OF HEALTH SERVICES AND WITH THE U.S. CENTER FOR DISEASE CONTROL AND PREVENTION FOR SEQUENCING POSITIVE CASES OF THE SARS-COV-2 VIRUS. ENHANCED SEQUENCING CAPABILITIES ALSO UNDERPIN PROJECTS LIKE MINDCROWD, WHICH NOW HAS MORE THAN 225,000 TEST SUBJECTS FROM ACROSS THE GLOBE DRIVING A STUDY FOR HOW HEALTHY BRAINS WORK AT DIFFERENT AGES. ADVANCED GENOMIC SEQUENCING WILL BE THE BACKBONE OF AN ANTI-CANCER DRUG DEVELOPMENT PROGRAM. BASED ON THE GENOMIC PROFILE OF EACH PATIENT, THIS PROJECT WILL EMPLOY THE RETRAINING OF IMMUNE SYSTEM CELLS - TAKEN OUT OF THE PATIENT, MULTIPLIED IN THE LAB, AND THEN RETURNED TO THE SAME PATIENT - TO FIGHT THE CANCER. IN ADDITION, AN ANTI-CANCER VACCINE IS BEING DEVELOPED THAT WOULD FURTHER STIMULATE THE IMMUNE SYSTEM AGAINST THE TUMOR. THEORETICALLY, THIS APPROACH COULD BE APPLIED TO NUMEROUS TYPES OF CANCER. TGEN'S PARTNERSHIPS HAVE RESULTED IN VARIOUS MULTI-YEAR, MULTI-MILLION DOLLAR EFFORTS FUNDED BY THE NATIONAL INSTITUTES OF HEALTH IN VARIOUS AREAS. ADDITIONALLY, TGEN INVESTIGATORS WERE AWARDED GRANTS IN MULTIPLE FIELDS, INCLUDING NEUROGENOMICS, CANCER THERAPEUTICS AND TREATMENTS, AND DISEASE DETECTION AND MONITORING. TGEN ADVANCED A SERIES OF INNOVATIVE RESEARCH INITIATIVES THAT YIELDED NUMEROUS SCIENTIFIC DISCOVERIES (MANY WITH POTENTIAL CLINICAL APPLICATION), ESTABLISHED NATIONAL AND INTERNATIONAL COLLABORATIONS, AND LED NEW AND EXCITING CLINICAL TRIALS WITH PROMISING RESULTS IN THE AREAS OF PATHOGENIC DISEASE, CANCER DIAGNOSIS AND MONITORING, NEUROGENOMICS, AND CANINE CANCER. SPECIFICALLY, TGEN INVESTIGATORS ARE SEQUENCING SAMPLES FROM COVID-19 PATIENTS TO ANALYZE THE VIRUS' GENETIC CODES AND TRACK ITS DIFFERENT STRAINS, ANALYZING DNA SHED INTO A PATIENT'S BLOODSTREAM TO PROVIDE A NONINVASIVE MEANS OF DETECTING THE PRESENCE OF A TUMOR, USING BLOOD SAMPLES AND A UNIQUE PROTEOMICS-BASED TECHNOLOGY TO DEVELOP A TEST TO IDENTIFY INFINITESIMALLY SMALL BREAST CANCER BIOMARKERS SHED INTO THE BLOODSTREAM, CREATING A COMPREHENSIVE RNA TRANSCRIPTOMIC RESOURCE FROM WHOLE BLOOD SAMPLES FOR USE BY THE PARKINSON'S RESEARCH COMMUNITY FOR BIOMARKER DEVELOPMENT ALLOWING SCIENTISTS TO INTERROGATE GENES, PATHWAYS AND MECHANISMS THAT PLAY A ROLE IN THE GENESIS AND PROGRESSION OF PARKINSON'S, ASSESSING THE RELATIONSHIP BETWEEN SMOKING, CARDIOVASCULAR DISEASE AND VERBAL MEMORY, AND IDENTIFYING A GENE THAT COULD NOT ONLY REDUCE THE DEPOSITION OF A HARD PLAQUES IN THE BARIN THAT LEADS TO ALZHEIMER'S DISEASE BUT ALSO MIGHT PREVENT OR DELAY THIS MEMORY-ROBBING DISEASE FROM DEVELOPING. TGEN INVESTIGATORS PUBLISHED THEIR RESEARCH RESULTS EXTENSIVELY IN SCHOLARLY PEER-REVIEWED ACADEMIC JOURNALS AND PRESENTED VIRTUALLY AT LEADING NATIONAL AND INTERNATIONAL CONFERENCES; INCLUDING PUBLICATION IN LEADING SCIENTIFIC JOURNALS SUCH AS PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, CANCER RESEARCH, SCIENCE TRANSLATIONAL MEDICINE, NATURE AGING AND MECHANISMS OF DISEASE, NATURE COMMUNICATIONS, AND PRESENTATIONS AT LEADING CONFERENCES SUCH AS THE AACR VIRTUAL SPECIAL CONFERENCE ON PANCREATIC CANCER. TGEN INVESTIGATORS FURTHER SERVE AS RESOURCES TO MEDICAL AND SCIENTIFIC RESEARCH CENTERS THROUGHOUT THE COUNTRY IN THEIR AREAS OF RESEARCH. IN EDUCATION AND OUTREACH, TGEN PROVIDED INTERNSHIPS TO STUDENTS IN PROGRAMS THAT FOCUSED ON DEVELOPING PROFESSIONAL AND SCIENTIFIC SKILLS. ADDITIONALLY, TGEN PROVIDED A BIOSCIENCE LEADERSHIP ACADEMY FOR STUDENTS WHERE THEY LEARNED ABOUT A VARIETY OF TOPICS WITHIN THE THEMES OF STEM PROFESSIONAL SKILLS, NETWORKING, LEADERSHIP, TRANSLATIONAL MEDICINE, AND HOT TOPICS IN THE BIOSCIENCES. FORM 990, PART VI, LINE 6 THE SOLE CORPORATE MEMBER OF TGEN IS CITY OF HOPE. FORM 990, PART VI, LINE 7A THE AFFILIATION AGREEMENT BETWEEN TGEN AND CITY OF HOPE GRANTS CITY OF HOPE THE RIGHT TO APPOINT DIRECTORS. FORM 990, PART VI, LINE 7B CERTAIN ACTIONS MAY NOT BE UNDERTAKEN WITHOUT THE PRIOR WRITTEN APPROVAL OF THE SOLE CORPORATE MEMBER, CITY OF HOPE, AS SPECIFIED IN THE GOVERNING DOCUMENTS OF TGEN, ON BEHALF OF ITSELF OR CERTAIN AFFILIATES, INCLUDING: BORROW OR LEND MONEY OR PLEDGE PROPERTY AS SECURITY; FIX COMPENSATION FOR DIRECTORS; CHANGE THE NUMBER OF VOTING DIRECTORS; ASSIGN, TRANSFER, PLEDGE, COMPROMISE OR RELEASE CERTAIN CLAIMS OR DEBTS; COMMENCE ASSIGNMENT FOR THE BENEFIT OF CREDITORS, PETITION FOR REORGANIZATION OR SIMILAR RELIEF OR ACTION; ACQUIRE, PURCHASE, DEVELOP, MATERIALLY IMPROVE, SELL, LEASE, OR MORTGAGE CORPORATE REAL ESTATE; MERGE, DISSOLVE OR SELL ALL OR SUBSTANTIALLY ALL ASSETS; ADOPT BUDGETS, STRATEGIC PLANS OR MATERIAL CHANGES TO OPERATIONS; FORM AFFILIATES OR MAKE BUSINESS INVESTMENTS; ADOPT, REPEAL OR AMEND KEY GOVERNING DOCUMENTS; EXERCISE CERTAIN GOVERNANCE RIGHTS; INCUR LIABILITIES OR CONTRACT OTHER THAN FOR FAIR CONSIDERATION AND IN THE ORDINARY COURSE OF BUSINESS. FORM 990, PART VI, LINE 11B THE FORM 990 IS PREPARED BY AN OUTSIDE ACCOUNTING FIRM BASED ON INFORMATION PROVIDED BY THE TGEN FINANCE DEPARTMENT. THE FORM 990 IS THEN REVIEWED BY THE FINANCE DEPARTMENT, OTHER MEMBERS OF MANAGEMENT AND THE AUDIT AND COMPLIANCE COMMITTEE OF THE CITY OF HOPE. THE FORM 990 IS POSTED ON THE BOARD WEBSITE FOR BOARD REVIEW PRIOR TO FILING WITH THE IRS. FORM 990, PART VI, LINE 12C TGEN DISTRIBUTES A CONFLICT OF INTEREST QUESTIONNAIRE ANNUALLY TO ALL DIRECTOR LEVEL POSITIONS AND ABOVE, IN ADDITION TO ANY OFFICERS AND KEY EMPLOYEES DESIGNATED BY THE CONFLICT OF INTEREST COMMITTEE. THE QUESTIONNAIRES ARE REVIEWED BY TGEN'S FINANCE DEPARTMENT AND THE OFFICE OF RESEARCH COMPLIANCE. THOSE EMPLOYEES WITH CONFLICTS ARE SENT FOR FURTHER REVIEW TO THE CONFLICT OF INTEREST COMMITTEE TO ENSURE AN APPROPRIATE PLAN IS SET FORTH. UPDATES TO THE LIST ARE HANDLED ON AN AS-NEEDED BASIS, BASED ON CONTRACT REVIEWS AND EMPLOYEE INFORMATION. FORM 990, PART VI, LINES 15A AND 15B THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF THE MEMBER SHALL BE THE EXECUTIVE COMPENSATION COMMITTEE OF TGEN. THE COMPENSATION REVIEW PROCESS WAS LAST COMPLETED IN 2021. FORM 990, PART VI, LINE 19 TGEN'S ARTICLES OF INCORPORATION ARE AVAILABLE TO THE PUBLIC THROUGH THE ARIZONA CORPORATION COMMISSION. TGEN'S AUDITED FINANCIAL STATEMENTS AND ITS CONFLICT OF INTEREST POLICIES ARE AVAILABLE BY WRITTEN REQUEST MADE TO THE CFO AND CONFLICT OF INTEREST MANAGER, RESPECTIVELY. TGEN'S BYLAWS ARE NOT MADE AVAILABLE TO THE PUBLIC. FORM 990 PART IX LINE 11G DESCRIPTION:CONSORTIUM/CONTRACTUAL TOTAL FEES:2142232 FORM 990 PART IX LINE 11G DESCRIPTION:OUTSIDE RESEARCH SERVICES TOTAL FEES:3532591 FORM 990 PART IX LINE 11G DESCRIPTION:CONSULTING TOTAL FEES:7227816 FORM 990 PART IX LINE 11G DESCRIPTION:TEMPORARY SERVICES TOTAL FEES:181062 THE CENTER FOR TRANS DRUG DEVELOPMENT 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 432047329 DRUG DEVEL AZ 0 0 TGAM LLC TGEN ACCELERATORS LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 753065445 GENOMICS AZ 0 0 TGEN TRANSLATIONAL SYSTEMS LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 461309498 ADV RESEARCH AZ 0 0 TGEN VIDIUM LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 843319906 ANIMAL DIAG AZ 56359 2730833 TGEN TGEN HEALTH VENTURES LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 464520712 HEALTHCARE AZ 0 0 TGEN DROPWISE LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 811959403 RESEARCH AZ 0 7740 TGAM LLC ID ORIGINS LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 753065445 TECH TRANSFER AZ 0 0 TGAM LLC PROFERO LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 753065445 LICENSING DE 0 0 TGEN METRICBIO LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 814455083 RESEARCH DE 0 10233 TGEN PMED MANAGEMENT LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 383922888 HEALTHCARE AZ 0 0 TGEN HV LLC PRECISION MEDICINE FACILITIES LLC 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 822560090 REAL ESTATE AZ 7058807 45657800 TGEN Ashion Analytics 445 N 5th Street Suite 600 Phoenix AZ 85004 454587602 Healthcare AZ 10476110 0 Ashion PMed TGEN RESEARCH INSTITUTE FOUNDATION 445 N 5TH STREET SUITE 600 PHOENIX AZ 85004 331092191 FUNDRAISING AZ 501(c)(3) 7 TGEN true CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE CA 91010 953435919 FUNDRAISING CA 501(c)(3) 7 NA false CITY OF HOPE NATIONAL MEDICAL CENTER 1500 EAST DUARTE ROAD DUARTE CA 91010 951683875 HOSPITAL CA 501(c)(3) 3 CITY OF HOPE true BECKMAN RESEARCH INSTITUTE 1450 EAST DUARTE ROAD DUARTE CA 91010 953432210 RESEARCH CA 501(c)(3) 4 CITY OF HOPE true CITY OF HOPE MEDICAL FOUNDATION 1500 EAST DUARTE ROAD DUARTE CA 91010 272803222 HEALTHCARE CA 501(c)(3) 3 CITY OF HOPE true SOUTHERN CA RADIATION ONCOLOGY PO BOX 19067 DALLAS TX 75381 364887584 MGMT SERVICES CA NA N/A false false AccessHope LLC 1500 E Duarte Rd Duarte CA 91010 842818450 Oncology Support CA NA N/A false false false false true false true false false false false false false true false true true false true false false TGEN RESEARCH INSTITUTE FOUNDATION c 12765361 ACTUAL COST TGEN RESEARCH INSTITUTE FOUNDATION q 2555009 ACTUAL COST CITY OF HOPE NATIONAL MEDICAL CENTER o 1163744 ACTUAL COST SCHEDULE R, PART III IDENTIFICATION OF RELATED ORGANIZATIONS TAXABLE AS A PARTNERSHIP NAME: SOUTHERN CA RADIATION ONCOLOGY EIN: 36-4887584 ADDRESS: 1500 EAST DUARTE ROAD, DUARTE, CA 91010 NAME: ACCESSHOPE LLC EIN: 84-2818450 ADDRESS: 1500 EAST DUARTE ROAD, DUARTE, CA 91010